Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06561308
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-17
Brief Title:
Clinical Efficacy Study of Pucotenlimab Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-arm Multicenter Phase II Study of Pucotenlimab Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer in Clinical Efficacy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitors on advanced stage III-IV endometrial cancer
Detailed Description:
Conduct domestic multicenter prospective phase II single arm clinical trials to answer the following questions
1 Evaluate the impact of neoadjuvant chemotherapy combined with PD-1 inhibitor on the remission rate surgical complications and surgical resection rate of advanced stage III-IV endometrial cancer
2 Evaluate the effect of of neoadjuvant chemotherapy combined with PD-1 inhibitors on the survival of patients with advanced III-IV endometrial cancer
3 Exploring the changes in tumor local immune related factors and cells before and after neoadjuvant chemotherapy and PD-1 inhibitor use as well as the responsiveness of different molecular subtypes of endometrial cancer to neoadjuvant therapy and screen for biological indicators that predict the effectiveness of PD-1 inhibitors
1 Evaluate the impact of neoadjuvant chemotherapy combined with PD-1 inhibitor on the remission rate surgical complications and surgical resection rate of advanced stage III-IV endometrial cancer
2 Evaluate the effect of of neoadjuvant chemotherapy combined with PD-1 inhibitors on the survival of patients with advanced III-IV endometrial cancer
3 Exploring the changes in tumor local immune related factors and cells before and after neoadjuvant chemotherapy and PD-1 inhibitor use as well as the responsiveness of different molecular subtypes of endometrial cancer to neoadjuvant therapy and screen for biological indicators that predict the effectiveness of PD-1 inhibitors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None